AIDS Healthcare Foundation Worried as FDA Inches Closer to Approving Drug That Might Prevent HIV Transmission
Last week, a committee of experts recommended that the Food and Drug Administration approve the first drug for protecting against HIV transmission.
The AIDS Healthcare Foundation says one problem is that the FDA doesn't think a registry of patients taking the drug for preventive means is needed, nor does it think those people should be required to be tested for HIV on a regular basis after they are given a prescription.
"The fact that a 'black market' has cropped up in response to Gilead's campaign to obtain FDA approval for Truvada shows what a dangerous game Gilead is playing," said Michael Weinstein, President of AIDS Healthcare Foundation. "The increased demand that has been created by Gilead's reckless push to have Truvada approved prematurely for this new use is only a preview of what is to come. If the company succeeds, Gilead will have free reign [sic] to market Truvada to HIV-negative individuals. This will open up a demand for the drug that will inevitably create an even bigger 'black market,' ultimately resulting in increased infections, viral resistance and a huge step backwards in efforts to fight the epidemic."
Get the This Week's Top Stories Newsletter
Every week we collect the latest news, music and arts stories — along with film and food reviews and the best things to do this week — so that you’ll never miss New Times Broward-Palm Beach's biggest stories.
- 27 Facts About New Miami Dolphins Head Coach Dan Campbell
Thu., Oct. 15, 7:00pm
Thu., Oct. 15, 7:30pm
Sat., Oct. 17, 12:00am
Sat., Oct. 17, 10:00am
- Sun-Sentinel to Make Employee Cutbacks
- Stabbing at Davie Group Home Again Highlights Lax Supervision